

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Unless the context requires otherwise, terms used in this announcement shall have the same meanings as those defined in the Prospectus (as defined below).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Prospective investors should read the prospectus dated 18 October 2013 (the “Prospectus”) issued by New Ray Medicine International Holding Limited (the “Company”) for detailed information about the Placing described below before deciding whether or not to invest in the Placing Shares thereby being offered.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited
新銳醫藥國際控股有限公司
(Incorporated in Bermuda with limited liability)

**NOTICE OF LISTING BY WAY OF PLACING
ON
THE GROWTH ENTERPRISE MARKET
OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

Number of Placing Shares : 280,000,000 Placing Shares
Placing Price : HK\$0.25 per Placing Share (payable
in full upon application in Hong Kong
dollars, plus brokerage fee of 1%,
SFC transaction levy of 0.003% and
Stock Exchange trading fee of 0.005%)
Nominal Value : HK\$0.01 per Share
Stock Code : 8180

Sole Sponsor

SUNWAH KINGSWAY
新華滙富

Kingsway Capital Limited

Sole Bookrunner and Sole Lead Manager

SUNWAH KINGSWAY
新華滙富

Kingsway Financial Services Group Limited

Co-Lead Managers



Trinity Finance Investment Limited



Astrum Capital Management Limited

Printed copies of the Prospectus required by the GEM Listing Rules and the Companies Ordinance are available, for information purposes only, at the offices of Kingsway Capital Limited and Kingsway Financial Services Group Limited at 7/F, Tower One, Lippo Centre, 89 Queensway, Hong Kong; during normal office hours from 9:00 a.m. to 5:00 p.m. from 18 October 2013 to and including 25 October 2013 (both dates inclusive).

Pursuant to the Underwriting Agreement, the Company is offering 280,000,000 Placing Shares for subscription by way of Placing at the Placing Price, on and subject to the terms and conditions set out in the Prospectus and the Underwriting Agreement. It is expected that the Underwriter; on behalf of the Company, will conditionally place 280,000,000 at the Placing Price to selected individual, professional and institutional investors in Hong Kong.

Application has been made to the Stock Exchange for the listing of, and permission to deal in, the Placing Shares issued and to be issued pursuant to the Capitalisation Issue, the Placing and any Shares which may fall to be allotted and issued upon the exercise of any options that may be granted under the Share Option Scheme as described in the Prospectus.

Applications for the Placing Shares will only be considered on the basis of the terms and conditions as set out in the Prospectus and the Underwriting Agreement.

The Placing is conditional upon the fulfillment of the conditions as set out in the paragraph headed “Conditions of the Placing” in the section headed “Structure and conditions of the Placing” in the Prospectus. If such conditions are not fulfilled or (where applicable) waived in accordance with the terms and conditions of the Underwriting Agreement on or before the dates and times as specified therein, the Placing will lapse and thereafter, all money received will be refunded to applicants of the Placing shares without interest and the Stock Exchange will be notified immediately. Notice of the lapse of the Placing will be published by the Company on the GEM Website at www.hkgem.com and the Company’s website at www.newraymedicine.com on the next business day immediately following the date of such lapse.

The Placing is managed by the Sole Lead Manager (for itself and on behalf of the Underwriters) on a fully underwritten basis. Prospective investors of the Placing Shares should note that the Sole Lead Manager (for itself and on behalf of the Underwriters) are entitled to terminate the Underwriting Agreement with immediate effect by giving notice in writing to the Company upon the occurrence of any of the events set forth under the paragraph headed “Grounds for termination” in the section headed “Underwriting” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date, which is expected to be 25 October 2013.

Subject to the granting of the listing of, and permission to deal in, the Shares on GEM as mentioned in the Prospectus and the compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date, or on any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made for the Shares to be admitted into CCASS.

The Placing Price will be HK\$0.25 per Placing Share. The Company will not issue temporary documents of title. No receipt will be issued for application monies paid. Share certificates for the Placing Shares will only become valid documents of title when the Placing has become unconditional in all respects and the Underwriting Agreement has not been terminated in accordance with its term prior to 8:00 a.m. (Hong Kong time) on the Listing Date.

The announcement of the indication of interest in the Placing and the basis of allocation of the Placing Shares will be published on the GEM Website at www.hkgem.com and the Company's website at www.newraymedicine.com on or before 24 October 2013.

Dealings in the Shares on GEM are expected to commence at 9:00 a.m. on Friday, 25 October 2013. Shares will be traded in board lots of 8,000 Shares. The stock code for the Shares is 8180.

By Order of the Board
New Ray Medicine International Holding Limited
Zhou Ling
Chairman and Executive Director

Hong Kong, 18 October 2013

As at the date of this announcement, the executive Directors are Mr. Zhou Ling, Mr. Dai Haidong, Ms. Yang Fang and Mr. Lee Chik Yuet; and the independent non-executive Directors are Mr. Ho Hau Cheung, BBS, MH, Mr. Sung Hak Keung, Andy and Mr. Leung Chi Kin.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement and a copy of the Prospectus will remain on the GEM Website at www.hkgem.com and, in the case of the announcement, on the “Latest Company Announcements” page for at least 7 days from the date of its posting. This announcement and a copy of the Prospectus will also be published on the Company’s website at www.newraymedicine.com.